European Urology Oncology

Slides:



Advertisements
Similar presentations
Volume 60, Issue 5, Pages (November 2011)
Advertisements

Volume 71, Issue 2, Pages (February 2017)
Analysis of endometrial carcinoma in young women at a high-volume cancer center  Alper Biler, Ulas Solmaz, Selcuk Erkilinc, Mehmet Gokcu, Mustafa Bagci,
Outcomes of Induction Chemotherapy Plus Intensity-Modulated Radiotherapy (IMRT) Versus IMRT Plus Concurrent Chemotherapy for Locoregionally Advanced.
European Urology Focus
Volume 58, Issue 2, Pages (August 2010)
The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis  K.
European Urology Oncology
Improved clinical outcomes in patients undergoing coronary artery bypass grafting with coronary endarterectomy  Oz M Shapira, MD, Gabriel Akopian, Ali.
Volume 68, Issue 3, Pages (September 2015)
Volume 69, Issue 1, Pages (January 2016)
European Urology Oncology
Histologic Grading of Noninvasive Papillary Urothelial Neoplasms
Volume 74, Issue 2, Pages (August 2018)
Volume 72, Issue 5, Pages (November 2017)
European Urology Oncology
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 61, Issue 5, Pages (May 2012)
Volume 72, Issue 4, Pages (October 2017)
Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis  Mohamad B. Sonbol, Belal Firwana, Talal.
European Urology Oncology
Volume 68, Issue 1, Pages (July 2015)
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma  Viktor Grünwald, Xun Lin, Daniel Kalanovic,
European Urology Oncology
Volume 69, Issue 4, Pages (April 2016)
European Urology Oncology
Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients  Timo F.W. Soeterik,
Volume 65, Issue 6, Pages (June 2014)
Volume 61, Issue 6, Pages (June 2012)
Volume 64, Issue 4, Pages (October 2013)
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
Volume 66, Issue 6, Pages (December 2014)
Volume 74, Issue 2, Pages (August 2018)
Volume 53, Issue 1, Pages (January 2008)
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
European Urology Oncology
European Urology Oncology
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
European Urology Oncology
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
European Urology Oncology
European Urology Oncology
Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors  Benny Weksler, MD, Anthony Holden, MD, Jennifer.
Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study  J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.
Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder  Devin N. Patel, Michael Luu, Zachary.
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
European Urology Oncology
European Urology Oncology
Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases
Matthew J. Bott, MD, Hanghang Wang, BA, William Travis, MD, Gregory J
European Urology Oncology
Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.
Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas  Debra Nana Yeboa, James B. Yu,
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
European Urology Oncology
Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.
European Urology Oncology
Fig. 1. Kaplan-Meier curves for PFS and OS
European Urology Oncology
European Urology Oncology
Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.
Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (
Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.
Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;
European Urology Oncology
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.
Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.
Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.
Presentation transcript:

European Urology Oncology Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study  Petros Grivas, Aly-Khan A. Lalani, Gregory R. Pond, Rebecca J. Nagy, Bishoy Faltas, Neeraj Agarwal, Sumati V. Gupta, Alexandra Drakaki, Ulka N. Vaishampayan, Jue Wang, Pedro C. Barata, Dharmesh Gopalakrishnan, Gurudatta Naik, Bradley A. McGregor, Lesli A. Kiedrowski, Richard B. Lanman, Guru P. Sonpavde  European Urology Oncology  DOI: 10.1016/j.euo.2019.02.004 Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 1 Kaplan-Meier curves for failure-free survival (FFS) and overall survival (OS) for patients with advanced urothelial carcinoma harboring alterations in (A, C) BRCA1 or (B, D) RAF1. HR=hazard ratio. European Urology Oncology DOI: (10.1016/j.euo.2019.02.004) Copyright © 2019 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.